Renewed Hope for BTK Inhibitor MS treatments
Earlier this year, I wondered whether it was time to give up my hope that researchers were close to developing a Bruton tyrosine kinase (BTK) inhibitor – a treatment that could pump the brakes on multiple sclerosis (MS) progression, particularly in primary progressive MS (PPMS). The US Food and Drug Administration (FDA) had just decided not to approve the experimental BTK inhibitor tolebrutinib in its current form. But the findings…Continue Reading